Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

National Commission on AIDS

Executive Summary

Met July 11 to discuss a draft of a report to be submitted to Congress Sept. 19 that will make recommendations on various AIDS issues. The panel discussed criteria for orphan drug status, suggesting that a drug grossing over $ 200 mil. per year should lose its orphan status. The committee later decided to withhold the specific numeric figure from the draft report while further considering the proposal. Public distribution of any future AIDS vaccine was also discussed; it was suggested that such a vaccine should be administered to the public without charge, "like a Salk vaccine." The commission will meet again Aug. 7 to discuss final changes to the draft.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019461

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel